The Prosigna assay is the only genomic assay that is CE-marked and FDA-cleared that was trained, verified and validated to provide an accurate estimate of the risk of distant recurrence in hormone receptor positive breast cancer using RNA from FFPE breast cancer patient samples. Here, NR4A1 is linked to breast cancer.